ABIVAX SA-ADR (ABVX) Stock Price & Overview
NASDAQ:ABVX • US00370M1036
Current stock price
The current stock price of ABVX is 118.08 USD. Today ABVX is up by 2.71%. In the past month the price decreased by -1.54%. In the past year, price increased by 2061.09%.
ABVX Key Statistics
- Market Cap
- 9.337B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.60
- Dividend Yield
- N/A
ABVX Stock Performance
ABVX Stock Chart
ABVX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ABVX. When comparing the yearly performance of all stocks, ABVX is one of the better performing stocks in the market, outperforming 99.88% of all stocks.
ABVX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ABVX. ABVX may be in some trouble as it scores bad on both profitability and health.
ABVX Earnings
On March 23, 2026 ABVX reported an EPS of -2.6 and a revenue of 2.48M. The company missed EPS expectations (-112.47% surprise) and beat revenue expectations (21.72% surprise).
ABVX Forecast & Estimates
14 analysts have analysed ABVX and the average price target is 154.7 USD. This implies a price increase of 31.01% is expected in the next year compared to the current price of 118.08.
For the next year, analysts expect an EPS growth of -20.7% and a revenue growth 29.38% for ABVX
ABVX Groups
Sector & Classification
ABVX Financial Highlights
Over the last trailing twelve months ABVX reported a non-GAAP Earnings per Share(EPS) of -2.6. The EPS increased by 18.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ABVX Ownership
ABVX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.29 | 380.121B | ||
| AMGN | AMGEN INC | 15.35 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.95 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.19 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.98 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.1 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.85 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.39 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ABVX
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
IPO: 2015-06-26
ABIVAX SA-ADR
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 69
Phone: 33153830963
ABIVAX SA-ADR / ABVX FAQ
What does ABVX do?
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
What is the stock price of ABIVAX SA-ADR today?
The current stock price of ABVX is 118.08 USD. The price increased by 2.71% in the last trading session.
What is the dividend status of ABIVAX SA-ADR?
ABVX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ABVX stock?
ABVX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of ABIVAX SA-ADR (ABVX)?
ABIVAX SA-ADR (ABVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.6).
Is ABIVAX SA-ADR (ABVX) expected to grow?
The Revenue of ABIVAX SA-ADR (ABVX) is expected to grow by 29.38% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the short interest for ABVX stock?
The outstanding short interest for ABIVAX SA-ADR (ABVX) is 4.35% of its float.